Regeneron (REGN) Stock Price

$598.2 0%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    6

  • Fundamental

    6

  • Technical

    5

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Regeneron, AI stock picks, stock alerts and much more.

Sign up

REGN AI Stock Analysis

AI stock analysis for REGN is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Regeneron (REGN) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Regeneron (REGN) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Regeneron (REGN), currently trading at $598.2, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About REGN

LSE

  • Regeneron Pharmaceuticals, Inc.

  • Symbol

    REGN

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    62.3B

Similar Stocks

CPRX Catalyst Pharmaceuticals
CPRX		 $20.56
1.1%
8
INO Inovio Pharmaceuticals
INO		 $1.91
3.2%
3
MRNA Moderna
MRNA		 $26.22
2.5%
3
AVXL Anavex Life Sciences
AVXL		 $9.55
1.3%
5
BBIO BridgeBio Pharma
BBIO		 $50.23
2.8%
6

News

FDA Extends Review Period of REGN's Submission for Eylea HD

FDA Extends Review Period of REGN's Submission for Eylea HD
August 21, 2025. zacks.com
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
August 20, 2025. globenewswire.com
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?

Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
August 15, 2025. zacks.com
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
August 4, 2025. benzinga.com

REGN Alternative Data

Web Traffic

Regeneron receives an estimated 373107 monthly visitors to regeneron.com.

  • Web Traffic

    373107

  • Change from Previous Month

    22%

  • 3 Month Change

    16.7%

  • YoY Change

    16.7%

Twitter Followers

Regeneron has 33,369 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.2% over the last month.

  • Twitter Followers

    33369

  • Daily Change

    0%

  • 1 Month Change

    0.2%

  • 3 Month Change

    1.1%

  • YoY Change

    1.1%

Facebook Engagement

Regeneron has engaged 1,234 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    1234

  • Daily Change

    6.2%

  • 1 Month Change

    21.8%

  • 3 Month Change

    9.4%

  • YoY Change

    9.4%

Instagram Followers

Regeneron has 16,677 Instagram Followers on its main Instagram account, up by 1.1% over the last month.

  • Instagram Followers

    16677

  • Daily Change

    0.1%

  • 1 Month Change

    1.1%

  • 3 Month Change

    9.1%

  • YoY Change

    9.1%

LinkedIn Followers

571,760 are following Regeneron on LinkedIn, up by 1.6% over the last month.

  • LinkedIn Followers

    571760

  • Daily Change

    0.1%

  • 1 Month Change

    1.6%

  • 3 Month Change

    4.7%

Job Postings

Regeneron has an estimated 279 open job postings, which is down -1.1% over the last month.

  • Job Postings

    279

  • Daily Change

    0.7%

  • 1 Month Change

    1.1%

  • 3 Month Change

    5.7%

  • YoY Change

    5.7%

LinkedIn Employees

According to LinkedIn, Regeneron has 16,394 employees, down by -0.4% over the last month.

  • LinkedIn Employees

    16394

  • Daily Change

    0%

  • 1 Month Change

    0.4%

  • 3 Month Change

    2.5%

  • YoY Change

    2.5%

Reddit Mentions

Regeneron has been mentioned an estimated 1 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    1

  • Daily Change

    50%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Business Outlook

According to employee reviews, the business outlook among employees at Regeneron is 70 out of 100 (bullish).

  • Business Outlook

    70

  • Change from Previous Month

    0%

  • 3 Month Change

    2.8%

  • YoY Change

    2.8%

Reddit Sentiment

The sentiment Score for Regeneron is 53 out of 100, which represents a neutral sentiment.

  • Reddit Sentiment

    52.5714

  • Daily Change

    22.5%

  • 1 Month Change

    0%

  • 3 Month Change

    22.5%

News Mentions

Regeneron was mentioned 5 times in the news yesterday.

  • News Mentions

    5

  • Daily Change

    25%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

REGN Financials

REGN Key Metrics

  • Total Revenue

    $3B

  • Net Income

    $808.7M

  • Earnings per Share

    $7.58

  • Free cash flow

    $773.6M

  • EBITDA

    $1B

  • EBITDA Ratio

    0.34358

  • Total Assets

    $37.5B

REGN 2-year Revenue & Income
REGN 2-year Free Cash Flow

REGN Technicals

REGN SMA
REGN RSI

FAQ

What's the current price of Regeneron (REGN) Stock?
The price of an Regeneron (REGN) share is $598.2.

What's the market cap of Regeneron?
The current market cap of Regeneron is 62.3B.

Should I buy or sell REGN?
Regeneron shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Regeneron is better viewed as a hold or accumulate position while waiting for further developments.

Is Regeneron a good investment?
The current analysis of Regeneron's fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Regeneron's portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Regeneron (REGN) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Regeneron stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Regeneron (REGN) that investors often compare it to?
Regeneron (REGN) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for Regeneron's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Regeneron's stock price to be around $620.5 in 2026. Starting from the current price of $598.2, this represents a 3.7% change in price, indicating a neutral outlook for the stock.

How to buy Regeneron (REGN) Stock?
Regeneron stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Regeneron shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.